Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin

Liver International

Volumn 34, Issue 1, 2014, Pages 69-77

  Mandorfer, Mattias ^a,c   Payer, Berit A ^a,c   Scheiner, Bernhard ^a,c   Breitenecker, Florian ^b,c   Aichelburg, Maximilian C ^b,c   Grabmeier Pfistershammer, Katharina ^b,c   Rieger, Armin ^b,c   Trauner, Michael ^a,c   Peck Radosavljevic, Markus ^a,c   Reiberger, Thomas ^a,c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Universitatsklinik fur Dermatologie   (Austria)

^c Vienna HIV and Liver Study Group   (Austria)

Author keywords

Antiviral therapy; FSS; Hepatitis C; HIV; Pegylated interferon; Quality of life; Ribavirin; SF36

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; DEPRESSION; DISEASE SEVERITY; DRUG DOSE REDUCTION; FATIGUE; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MIXED INFECTION; PATIENT COMPLIANCE; QUALITY OF LIFE; RISK FACTOR; SHORT FORM 36; TREATMENT DURATION;

ANTIVIRAL THERAPY; FSS; HEPATITIS C; HIV; PEGYLATED INTERFERON; QUALITY OF LIFE; RIBAVIRIN; SF36;

ANEMIA; ANTIVIRAL AGENTS; COINFECTION; DRUG THERAPY, COMBINATION; FATIGUE; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MENTAL HEALTH; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; RECOMBINANT PROTEINS; RIBAVIRIN; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84890115492     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12253     Document Type: Article

References (30)

1. Smith C, Sabin CA, Lundgren JD, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010; 24: 1537-48.
2. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44(Suppl. 1): S6-9.
3. Reiberger T, Ferlitsch A, Sieghart W, et al. HIV-HCV co-infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension. J Viral Hepatitis 2010; 17: 400-9.
4. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33: 562-9.
5. Wandeler G, Gsponer T, Bregenzer A, et al. Hepatitis C virus infections in the Swiss HIV cohort study: a rapidly evolving epidemic. Clin Infect Dis 2012; 55: 1408-16.
6. Vogel M, Page E, Boesecke C, et al. Liver fibrosis progression after acute hepatitis C virus infection in HIV-positive individuals. Clin Infect Dis 2012; 54: 556-9.
7. Rockstroh J, Grint D, Boesecke C, et al. Increases in acute hepatitis C (HCV) incidence across Europe: which regions and patient groups are affected? J Int AIDS Soc 2012; 15(Suppl. 4): 18116.
8. Reiberger T, Obermeier M, Payer BA, et al. Considerable under-treatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life setting. Antiviral therapy 2011; 16: 815-24.
9. Mehta SH, Lucas GM, Mirel LB, et al. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS 2006; 20: 2361-9.
10. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27: 209-12.
11. Gillis J, Cooper C, Rourke S, et al. Impact of hepatitis B and C co-infection on health-related quality of life in HIV positive individuals. Qual Life Res 2013; 22: 1525-35.
12. Kemmer N, Hua L, Andersen JW, et al. Health-related quality of life in subjects with HCV/HIV coinfection: results from ACTG 5178 study. J Viral Hepatitis 2012; 19: 792-800.
13. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-50.
14. Reiberger T, Kosi L, Maresch J, et al. Mitochondrial toxicity is associated with virological response in patients with HIV and hepatitis C virus coinfection treated with ribavirin and highly active antiretroviral therapy. J Infect Dis 2010; 202: 156-60.
15. Reiberger T, Payer BA, Kosi L, et al. Concomitant highly active antiretroviral therapy leads to smaller decline and faster recovery of CD4+ cell counts during and after pegylated interferon plus ribavirin therapy in HIV-hepatitis C virus coinfected patients. J Infect Dis 2011; 203: 1802-6.
16. Fransen Van De Putte DE, Fischer K, Posthouwer D, Mauser-Bunschoten EP. The burden of HCV treatment in patients with inherited bleeding disorders. Haemophilia 2011; 17: 791-9.
17. Jenkinson C, Coulter A, Wright L. Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ 1993; 306: 1437-40.
18. Krupp LB, Larocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46: 1121-3.
19. Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002; 35: 704-8.
20. Ware JE Jr, Bayliss MS, Mannocchia M, Davis GL. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response the interventional therapy group. Hepatology 1999; 30: 550-5.
21. Kleinman L, Zodet MW, Hakim Z, et al. Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C. Qual Life Res 2000; 9: 499-508.
22. Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy the consensus interferon study group. Hepatology 1999; 29: 264-70.
23. Samsa G, Edelman D, Rothman ML, et al. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics 1999; 15: 141-55.
24. Ware JE, Kosinski M, Keller S. SF-36 Physical and Mental Health Summary Scores: A User's Manual. Boston: The Health Institute, New England Medical Center 1994.
25. Mchorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31: 247-63.
26. Reiberger T, Payer BA, Ferlitsch A, et al. A prospective evaluation of pulmonary, systemic and hepatic hemodynamics in HIV-HCV coinfected patients prior and after antiviral therapy with pegylated interferon and ribavirin. Antiviral therapy 2012; 17: 1327-34
27. Reiberger T, Ferlitsch A, Payer BA, et al. Noninvasive screening for liver fibrosis and portal hypertension by transient elastography-a large single center experience. Wien Klin Wochenschr 2012; 124: 395-402.
28. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-50.
29. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292: 2839-48.
30. Dan AA, Martin LM, Crone C, et al. Depression, anemia and health-related quality of life in chronic hepatitis C. J Hepatol 2006; 44: 491-8.